AstraZeneca vaccine could be approved for emergency use in Thailand this week
Thailand’s Food and Drug Administration is likely to approve a Covid-19 vaccine developed by AstraZeneca in partnership with Oxford University as early as this week. The vaccine, already given the go-ahead in the US and UK, would be approved for emergency use, with administration likely to begin next month. Healthcare workers and those with underlying conditions will be prioritised.
Opas Karnkawinpong from the Disease Control Department says the FDA’s review of the vaccine’s efficacy and safety is going well. Thailand has fallen behind its neighbours in terms of vaccine administration, with a number of countries in the region already starting their roll-out. Indonesia kicked things off last week, with President Joko Widodo the first to receive China’s Sinovac jab.
Thailand is expected to take delivery of 200,000 doses of the Chinese vaccine next month, but questions linger over its efficacy, which was recently revised downwards by researchers in Brazil. The vaccine has not yet completed phase 3 trials and Thailand’s health officials say it may not gain FDA approval until February 14, as the manufacturer has no representation in the Kingdom.
Thailand has signed a technology-transfer agreement with AstraZeneca to produce that vaccine locally. The jab will be manufactured by Siam Bioscience, a pharmaceutical company owned by the Monarchy. Surachok Tangwiwat from the FDA says the doses currently subject to approval have been produced by other countries, but did not specify which ones, how many doses have been imported, or at what cost.
The AstraZeneca vaccine has completed phase 3 trials and has been shown to be 70% effective, less than the Pfizer and Moderna vaccines. However, the World Health Organisation has previously stated that a vaccine only needs to be over 50% effective to meet the global threshold for regulatory approval.
SOURCE: Coconuts
